On January 5, 2026 AbbVie (NYSE: ABBV) reported it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026. Management will participate in a fireside chat at 10:15 a.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

(Press release, AbbVie, JAN 5, 2026, View Source [SID1234661729])

On January 5, 2026 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company advancing innovative precision medicines, reported that Helen Sabzevari, PhD, President and Chief Executive Officer of Precigen, will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026 in San Francisco, California. Dr. Sabzevari’s company presentation is scheduled for Thursday, January 15, 2026 at 7:30 AM PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Dr. Sabzevari will participate in a fireside chat hosted by the Company’s commercialization operations partner, Eversana, on Monday, January 12, 2026 at 10:30 AM PT at the Biotech Showcase, which runs January 12–14, 2026 in San Francisco.

Participants may view details for these events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.

(Press release, Precigen, JAN 5, 2026, View Source [SID1234661728])

On January 5, 2026 Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) reported that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, in San Francisco. Krish S. Krishnan, Chairman and Chief Executive Officer, is scheduled to give a presentation at 10:30 am ET / 7:30 am PT and host investor meetings throughout the day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available here beginning at 10:30 am ET / 7:30 am PT on Monday, January 12, 2026 and will be posted on the Investors section of the Company’s website.

(Press release, Krystal Biotech, JAN 5, 2026, View Source [SID1234661727])

On January 5, 2026 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported it will present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. Pacific Time on Monday, January 12, 2026, in San Francisco. Kyle Gano, Chief Executive Officer, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and can be accessed on Neurocrine Biosciences’ website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

(Press release, Neurocrine Biosciences, JAN 5, 2026, View Source [SID1234661726])

On January 5, 2026 Sanofi K.K. (hereinafter "Sanofi") and Taiho Pharmaceutical Co., Ltd. (hereinafter "Taiho") reported that the sales of the anticancer agent Jevtana I.V. Infusion 60 mg (generic name: cabazitaxel; hereinafter "Jevtana") will be transferred from Sanofi to Taiho in Japan effective April 1, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jevtana is an anticancer agent which was approved and launched in Japan in 2014, indicated for patients with castration-resistant prostate cancer previously treated with a docetaxel-containing regimen. The agent inhibits cell division by promoting tubulin polymerization and stabilizing microtubules, thereby suppressing the proliferation of cancer cells.

On April 1, 2026, Taiho will assume responsibility for the sales and marketing, and medical information activities for Jevtana in Japan, while Sanofi will continue to be the marketing authorization holder and will also continue to manufacture the product.

Sanofi and Taiho remain committed to ensuring a smooth transition and continued supply of Jevtana to patients in need of this treatment.

(Press release, Taiho, JAN 5, 2026, View Source [SID1234661724])